Schonfeld Strategic Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.42M	Buy	407,470 +306,360	+303%	+$2.98M	0.02%	619
2026 Q1	$941K	Sell	101,110 -60,872	-38%	-$530K	0.01%	1126
2025 Q4	$1.21M	Sell	161,982 -17,093	-10%	-$173K	0.01%	1051
2025 Q3	$1.56M	Buy	+179,075	New	+$1.07M	0.01%	1167
2024 Q3	–	Sell	-14,273	Closed	-$300K	–	2154
2024 Q2	$300K	Buy	+14,273	New	+$358K	﹤0.01%	1688
2022 Q4	–	Sell	-11,100	Closed	-$89K	–	2718
2022 Q3	$89K	Sell	11,100 -18,200	-62%	-$165K	﹤0.01%	2578
2022 Q2	$205K	Buy	+29,300	New	+$285K	﹤0.01%	1868

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Schonfeld Strategic Advisors's FDMT Position: Q2 2026 in Review

Schonfeld Strategic Advisors increased its 4D Molecular Therapeutics (FDMT) stake by 303% in Q2 2026, buying an estimated $2.98M and bringing the position to 407,470 shares worth $5.42M. The position accounts for 0.02% of the portfolio, ranked #619.

Schonfeld Strategic Advisors first reported a position in FDMT in Q2 2022 and has held it in 7 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Schonfeld Strategic Advisors held 407,470 shares of 4D Molecular Therapeutics worth $5.42M as of Q2 2026.
Schonfeld Strategic Advisors bought 306,360 4D Molecular Therapeutics shares in Q2 2026, an estimated $2.98M.
4D Molecular Therapeutics made up 0.02% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #619 holding.
Schonfeld Strategic Advisors first reported a position in 4D Molecular Therapeutics in Q2 2022 and has held it in 7 quarters since.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.